Shows
Editors in ConversationUpdated FDA Recognition of CLSI Breakpoints (JCM ed.)Oversight and guidance for performing antibiotic susceptibility testing can be bewildering. There is an alphabet soup of agencies and bodies involved: FDA, CLSI, and USCAST, to name a few here in the US. How does the Food and Drug Administration, which has regulatory authority over AST, work with a nimble group like the Clinical Laboratory Standards Institute? Guests: Romney Humphries, Ph.D., D(ABMM), M(ASCP) Patricia Simner, Ph.D., D(ABMM) Links: Major updates to FDA-recognized Clinical and Laboratory Standards Institute breakpoints are a win for the fight against antimicrobial resistance J...
2025-05-3052 minEditors in ConversationBest Papers in the Journal of Clinical Microbiology, 2024The past year in Clinical Microbiology, as seen through the lens of the Journal of Clinical Microbiology. Four JCM editors have each selected a paper they consider to be among the "best" we published in 2024. Of course there are no objective criteria for what makes a paper the "best." So, by "best," we mean "a paper that I find exciting." View this episode: https://www.youtube.com/watch?v=fK9ZqZUrDiY Guests: Patricia Simner, Ph.D., D(ABMM), Johns Hopkins University School of Medicine Romney Humphries, Ph.D., D(ABMM), M(ASCP), Vanderbilt University M...
2025-02-141h 01Editors in ConversationFavorite Clinical Microbiology Papers of 2023 (JCM ed.)We managed to make it through 2023 without a major epidemic or pandemic, and as we get into the holiday spirit and look forward to the new year, some of us took a look back and picked out one of our favorite JCM paper published in 2023, which I will tell you, was no easy task as there were many of good ones to choose from! And personally, after looking through all the issues over the last year, it never ceases to amaze me the variety of topics that we publish on in JCM – including unique things like the evaluation of a...
2023-12-231h 05
Let's Talk Micro82: Discrepancies between phenotypic and genotypic testing in Microbiology pt.2This is part 2 of a two part series. Dr. Rachael Liesman goes over scenarios where genotypic and phenotypic testing do not match and what to do. What do you do when your molecular instrument detects mec-A and Staphylococcus aureus but your susceptibility report shows oxacillin susceptible? What about VanA and Enterococcus? As Medical Laboratory Scientists in Microbiology, we encounter this type of situations. Tune in to find out how to troubleshoot these discrepancies. Link to Dr. Patricia Simner's article: https://journals.asm.org/doi/full/10.1128/JCM.00138-20
2023-03-2430 min
Inside the LabS2E6: Antimicrobial Resistance--the Next Global Pandemic?The World Health Organization cites antimicrobial resistance, or AMR, as one of the top 10 global public health threats facing humanity. And according to the Centers for Disease Control and Prevention, at least 2.8 million people in the U.S. contract an antibiotic-resistant infection every year—and more than 35,000 die. What do laboratory professionals need to know about the emerging data around antimicrobial resistance? And what can we do in the lab to support infection prevention and control? On this episode of Inside the Lab, our hosts Dr. Lotte Mulder and Ms. Kelly Swails are joined by Dr. Patricia Sim...
2021-11-0248 minEditors in ConversationReconciling Genotypic and Phenotypic Susceptibility Tests (JCM ed.)Our options for susceptibility testing have greatly increased in recent years. In addition to classical phenotypic susceptibility testing by disk diffusion and measurement of the minimum inhibitory concentration, genotypic tests are increasingly available. Genotypic tests range from tests for a single organism and one resistance gene to tests for 20 or more organisms and multiple resistance genes. But what should the clinical microbiologist do when the results of phenotypic and genotypic are in conflict? Welcome to Editors in Conversation. This episode is brought to you by the Journal of Clinical Microbiology, available at jcm.asm.org and on...
2021-05-0140 minEditors in ConversationDetection of carbapenemases (JCM Journal)• How can the clinical laboratory detect carbapenemases, which are enzyme that can make bacteria resistant to some of the most potent or broad-spectrum antibiotics available? • What is the clinical significance of detecting such an enzyme? Does it affect the care of the patient? • Finally, what practical advice can we give to help labs decide which of the many available tests is the best one for them? The antibiotics we discuss are the "carbapenems," such as imipenem and meropenem. These are among the broadest spectrum antibiotics available. Bacteria that are resistant to carbapenems were i...
2020-08-2144 min